These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 30387392

  • 1. Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of β-amino di-Carbonyl Derivatives.
    Hadda TB, Rauf A, Zgou H, Senol FS, Orhan IE, Mabkhot YN, Althagafi II, Farghaly TA, Alterary S.
    Mini Rev Med Chem; 2019; 19(8):688-705. PubMed ID: 30387392
    [Abstract] [Full Text] [Related]

  • 2. Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM Analyses and Crystalline Structure of Pharmacophore Site.
    Hadda TB, Talhi O, Silva ASM, Senol FS, Orhan IE, Rauf A, Mabkhot YN, Bachari K, Warad I, Farghaly TA, Althagafi II, Mubarak MS.
    Mini Rev Med Chem; 2018; 18(8):711-716. PubMed ID: 28714400
    [Abstract] [Full Text] [Related]

  • 3. Spiro Heterocyclic Compounds as Potential Anti-Alzheimer Agents (Part 2): Their Metal Chelation Capacity, POM Analyses and DFT Studies.
    Hadda TB, Deniz FSS, Orhan IE, Zgou H, Rauf A, Mabkhot YN, Bennani B, Emam DR, Kheder NA, Asayari A, Muhsinah AB, Maalik A.
    Med Chem; 2021; 17(8):834-843. PubMed ID: 32520690
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
    Ghobadian R, Nadri H, Moradi A, Bukhari SNA, Mahdavi M, Asadi M, Akbarzadeh T, Khaleghzadeh-Ahangar H, Sharifzadeh M, Amini M.
    Bioorg Med Chem; 2018 Sep 15; 26(17):4952-4962. PubMed ID: 30190181
    [Abstract] [Full Text] [Related]

  • 5. Identification of New Chromenone Derivatives as Cholinesterase Inhibitors and Molecular Docking Studies.
    Iqbal J, Abbasi MSA, Zaib S, Afridi S, Furtmann N, Bajorath J, Langer P.
    Med Chem; 2018 Sep 15; 14(8):809-817. PubMed ID: 29473519
    [Abstract] [Full Text] [Related]

  • 6. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones.
    Shah MS, Khan SU, Ejaz SA, Afridi S, Rizvi SUF, Najam-Ul-Haq M, Iqbal J.
    Biochem Biophys Res Commun; 2017 Jan 22; 482(4):615-624. PubMed ID: 27865835
    [Abstract] [Full Text] [Related]

  • 7. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
    da Silva CH, Campo VL, Carvalho I, Taft CA.
    J Mol Graph Model; 2006 Oct 22; 25(2):169-75. PubMed ID: 16413803
    [Abstract] [Full Text] [Related]

  • 8. Acetamide Derivatives of Chromen-2-ones as Potent Cholinesterase Inhibitors.
    Prasad S, Kumar B, Kumar S, Chand K, Kamble SS, Gautam HK, Sharma SK.
    Arch Pharm (Weinheim); 2017 Aug 22; 350(8):. PubMed ID: 28699213
    [Abstract] [Full Text] [Related]

  • 9. Selective in vitro and in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from Perovskia atriplicifolia Benth. and Salvia glutinosa L.
    Senol FS, Ślusarczyk S, Matkowski A, Pérez-Garrido A, Girón-Rodríguez F, Cerón-Carrasco JP, den-Haan H, Peña-García J, Pérez-Sánchez H, Domaradzki K, Orhan IE.
    Phytochemistry; 2017 Jan 22; 133():33-44. PubMed ID: 27817931
    [Abstract] [Full Text] [Related]

  • 10. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
    Hameed A, Zehra ST, Shah SJ, Khan KM, Alharthy RD, Furtmann N, Bajorath J, Tahir MN, Iqbal J.
    Chem Biol Drug Des; 2015 Nov 22; 86(5):1115-20. PubMed ID: 25951978
    [Abstract] [Full Text] [Related]

  • 11. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
    Makhaeva GF, Lushchekina SV, Boltneva NP, Serebryakova OG, Rudakova EV, Ustyugov AA, Bachurin SO, Shchepochkin AV, Chupakhin ON, Charushin VN, Richardson RJ.
    Bioorg Med Chem; 2017 Nov 01; 25(21):5981-5994. PubMed ID: 28986116
    [Abstract] [Full Text] [Related]

  • 12. In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease.
    Ul-Haq Z, Khan W, Kalsoom S, Ansari FL.
    Theor Biol Med Model; 2010 Jun 16; 7():22. PubMed ID: 20550720
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
    Jung HA, Ali MY, Jung HJ, Jeong HO, Chung HY, Choi JS.
    J Ethnopharmacol; 2016 Sep 15; 191():152-160. PubMed ID: 27321278
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
    Szymański P, Janik A, Zurek E, Mikiciuk-Olasik E.
    Pharmazie; 2011 Jun 15; 66(6):399-403. PubMed ID: 21699076
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
    Hussein W, Sağlık BN, Levent S, Korkut B, Ilgın S, Özkay Y, Kaplancıklı ZA.
    Molecules; 2018 Aug 14; 23(8):. PubMed ID: 30110946
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
    Bajda M, Jończyk J, Malawska B, Czarnecka K, Girek M, Olszewska P, Sikora J, Mikiciuk-Olasik E, Skibiński R, Gumieniczek A, Szymański P.
    Bioorg Med Chem; 2015 Sep 01; 23(17):5610-8. PubMed ID: 26242241
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, Characterization and Cholinesterase Inhibition Studies of New Arylidene Aminothiazolylethanone Derivatives.
    Channar PA, Shah MS, Saeed A, Khan SU, Larik FA, Shabir G, Iqbal J.
    Med Chem; 2017 Sep 01; 13(7):648-653. PubMed ID: 28266279
    [Abstract] [Full Text] [Related]

  • 18. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
    Yu YF, Huang YD, Zhang C, Wu XN, Zhou Q, Wu D, Wu Y, Luo HB.
    ACS Chem Neurosci; 2017 Nov 15; 8(11):2522-2534. PubMed ID: 28783948
    [Abstract] [Full Text] [Related]

  • 19. Tetrahydroacridine derivatives with fluorobenzoic acid moiety as multifunctional agents for Alzheimer's disease treatment.
    Czarnecka K, Szymański P, Girek M, Mikiciuk-Olasik E, Skibiński R, Kabziński J, Majsterek I, Malawska B, Jończyk J, Bajda M.
    Bioorg Chem; 2017 Jun 15; 72():315-322. PubMed ID: 28501648
    [Abstract] [Full Text] [Related]

  • 20. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.
    Drugs Aging; 2004 Jun 15; 21(7):453-78. PubMed ID: 15132713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.